Parametric Portfolio Associates LLC boosted its position in shares of Steris PLC (NYSE:STE) by 6.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 150,207 shares of the medical equipment provider’s stock after purchasing an additional 9,545 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.18% of Steris worth $19,231,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its stake in Steris by 10,585.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,572,743 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 3,539,306 shares during the last quarter. Norges Bank purchased a new position in Steris in the 4th quarter worth $96,648,000. BlackRock Inc. raised its stake in Steris by 10.3% in the 4th quarter. BlackRock Inc. now owns 8,549,361 shares of the medical equipment provider’s stock worth $913,498,000 after acquiring an additional 800,900 shares during the last quarter. Millennium Management LLC raised its stake in shares of Steris by 1,457.4% during the 4th quarter. Millennium Management LLC now owns 607,474 shares of the medical equipment provider’s stock valued at $64,909,000 after buying an additional 568,469 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in shares of Steris by 55.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 958,036 shares of the medical equipment provider’s stock valued at $102,366,000 after buying an additional 340,204 shares during the last quarter. Institutional investors own 83.38% of the company’s stock.
In other Steris news, insider Kathleen Bardwell sold 5,360 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $145.05, for a total value of $777,468.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Karen L. Burton sold 1,387 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $133.89, for a total value of $185,705.43. The disclosure for this sale can be found here. Insiders sold 237,145 shares of company stock worth $32,091,848 over the last quarter. 2.36% of the stock is currently owned by insiders.
Steris (NYSE:STE) last issued its earnings results on Monday, May 13th. The medical equipment provider reported $1.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.09. Steris had a return on equity of 13.34% and a net margin of 10.93%. The business had revenue of $768.00 million for the quarter, compared to analysts’ expectations of $738.87 million. During the same period in the previous year, the firm posted $1.24 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities analysts anticipate that Steris PLC will post 5.37 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Wednesday, June 12th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Tuesday, June 11th. Steris’s dividend payout ratio is presently 27.81%.
A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Steris from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. JMP Securities lifted their price objective on Steris from $135.00 to $150.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 22nd. KeyCorp lifted their price target on Steris from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Wednesday, May 15th. Finally, Stephens lifted their price target on Steris from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, May 15th. Five research analysts have rated the stock with a buy rating, Steris currently has an average rating of “Buy” and a consensus target price of $148.20.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Story: Dividend Aristocrat Index
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.